Equities Analysts Issue Forecasts for ARTV FY2025 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Stock analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Artiva Biotherapeutics in a research note issued to investors on Thursday, August 7th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($3.22) per share for the year, down from their previous forecast of ($3.04). The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share. Cantor Fitzgerald also issued estimates for Artiva Biotherapeutics' FY2026 earnings at ($2.17) EPS.

Several other research analysts have also recently weighed in on ARTV. Needham & Company LLC lowered their price target on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. HC Wainwright raised shares of Artiva Biotherapeutics to a "buy" rating and set a $12.00 price target on the stock in a research report on Wednesday, June 11th.

Artiva Biotherapeutics Trading Up 0.5%

Shares of ARTV stock traded up $0.01 on Monday, hitting $2.71. 12,259 shares of the stock traded hands, compared to its average volume of 228,990. The firm's 50-day moving average price is $2.24 and its two-hundred day moving average price is $2.91. Artiva Biotherapeutics has a twelve month low of $1.47 and a twelve month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.03).

Institutional Trading of Artiva Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ARTV. Marshall Wace LLP purchased a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $79,000. Nuveen LLC purchased a new stake in Artiva Biotherapeutics during the first quarter worth about $144,000. Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics during the second quarter worth about $67,000. Qube Research & Technologies Ltd purchased a new stake in Artiva Biotherapeutics during the second quarter worth about $58,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the second quarter worth about $53,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.